A story of excellence, care and dedication. Since its creation, Blanver has always looked to the future and to the quality of life of patients.
Giuseppe Frangioni notes the need for national pharmaceutical Raw Materials of quality and founds Blanver.
Blanver's success leads to the founding of the pharmaceutical unit, which offered medical production outsourcing
Entry into the antiretroviral segment by outsourcing the production of drugs for treatment to official Brazilian Laboratories.
Blanver inaugurates its new Pharmaceutical Unit in Taboão da Serra - S investment in technology, research and development We start the development of our own drugs.
Tenofovir, a drug for the treatment of Hepatitis B, is the first launch of Brazil's first PDP.
Launch of Duplivir (Tenofovir + Lamivudine) from Blanver, an innovation in the treatment of combines two active ingredients in one with
New direction for the Pharmaceuticals Unit the development and production of its own drugs and enters the segment of Active Pharmaceutical Ingredients (APIs) segment through the company CYG Biotech.
In a strategic transformation, Blanver excipients and ingredients division.
Blanver registers the generic PrEP sim drug (tenofovir + entricitabine) indicated for HIV prevention . In participation in the private brazilian market sales of Binav. It also registers the generic drug sofosbuvir, indicated for the treatment of Hepatitis C. Start of IFA production (tenofovir) at the Indaiatuba unit for PDP care.
The company launches the first generic (tenofovir + entricitabine) in the Brazilian market. Launches also the first generic Osteoporosis treatment and prevention (raloxifene) in the Brazilian private market of the production of the batches registration of
Granted registration of generic Dol of the production of the lots of registration of
Rua Doutor Mario Augusto Pereira, 100, Galpão B, Jardim São Paulo, Taboão da Serra, São Paulo, CEP: 06767-330 • © Blanver 2020, Todos os direitos reservados